title: Biomarkers in Severe Asthma.
abstract: Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Biomarkers can play a role in these investigations as well by providing insight into the underlying biology in human studies of patients with severe asthma.
authors.affiliation: Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, 513 Parnassus Avenue, HSE 1305, San Francisco, CA 94143-0130, USA.
authors.forename: Xiao Chloe
authors.initials: XC
authors.lastname: Wan
authors.affiliation: Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, 513 Parnassus Avenue, HSE 1305, San Francisco, CA 94143-0130, USA. Electronic address: prescott.woodruff@ucsf.edu.
authors.forename: Prescott G
authors.initials: PG
authors.lastname: Woodruff
mesh_terms: D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D015415:Biomarkers; D000066491:Clinical Decision-Making; D006801:Humans; D011379:Prognosis; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D015415:Biomarkers
keywords: Biomarker; Endotype; Eosinophil; Exhaled nitric oxide; Periostin; Severe asthma